T-Heart Appoints Sarah Sorrel as Independent Board Member
29.11.2022 16:00:00 EET | Business Wire | Press release
T-Heart, a medtech company developing a truly novel and differentiated transcatheter tricuspid prosthetic heart valve specifically designed for tricuspid regurgitation, today announced it has appointed Sarah Sorrel as its first independent member of the Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221129005579/en/
(Photo: T-Heart)
Sarah Sorrel has more than 30 years’ experience in medical device regulation and clinical trials with an emphasis on emerging technologies. She founded and successfully managed MedPass International, a leading European CRO, regulatory and reimbursement consultancy, that specializes in medical device development and market access, before its acquisition by ICON plc in 2020. Sarah is American and holds a degree in Engineering and Applied Science from Yale University.
Sarah Sorrel joins the T-Heart Board of Directors when the company is preparing its First in Human / Early Feasibility Study, bringing a valuable experience and expertise to its execution. Soad El Ghazouani, CEO of T-Heart said: “We are excited to have an independent board member with such considerable experience in medtech, and more specifically in the transcatheter heart valve field, joining the board at T-Heart at a key moment for the company. Sarah’s experience and extensive knowledge of healthcare regulations will be an invaluable asset as we advance towards the clinic.”
Ms. Sorrel added: “I am honored to join the T-Heart Board of Directors and convinced that tricuspid is the next key step in the transcatheter heart valve field. I look forward to contributing to T-Heart’s important objective to bring a perfectly adapted and differentiated solution to patients suffering from severe tricuspid regurgitation and hopefully significantly improve their quality of life. “
Ms. Sorrel is the third female out of five representatives to join the board of T-Heart.
ABOUT T-HEART
T-Heart is a French MedTech company focused on the treatment of Tricuspid Regurgitation, a true medical unmet need. Tricuspid regurgitation is a progressive condition in which blood leaks backward through the tricuspid valve, potentially leading to heart failure and death. The transcatheter tricuspid market represents a $3.0+ billion potential opportunity, although currently, limited treatment options exist to address this market.
T-Heart has developed a truly novel and differentiated transcatheter tricuspid prosthetic heart valve specifically designed for tricuspid heart valve regurgitation, thereby addressing the specific anatomical challenges. Moreover, T-Heart's unique design enables the interventional cardiologist to replace the diseased tricuspid valve with a simple one-step technique and allows for broad applicability to a larger patient population with minimal device sizes.
T-Heart was co-founded in late 2018 with iBionext, a company builder and investor that supports and finances the development of companies with a strong technological breakthrough in HealthTech in Paris, France.
Since its inception, T-Heart has assembled an impressive team, comprised of management and external experts, has successfully proved the concept through pre-clinical testing and initiated its Q-Sub for EFS with the FDA.
For more information:
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221129005579/en/
Contact information
T-HEART
Soad El-Ghazouani +33 (0)1 85 73 27 05
selghazouani@theartvalve.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alushibe Holding Group to Bring 12 Global F&B Brands to Libya by 202829.10.2026 10:00:00 EET | Press release
Alushibe Holding Group today announced plans to bring 12 international food-and-beverage brands to Libya by 2028 through its Retail & Destinations division, beginning with an exclusive master franchise agreement with MADO, the Turkish ice-cream and patisserie house founded in 1850. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029822317/en/ Ahmed Gadalla signs exclusive master franchise agreement with Türkiye's MADO: US$7 million, 7 cafés and 350 jobs in the first phase; 1,000 sq m Benghazi flagship opens Q1 2027 – (Photo: AETOSWire) Signed in Kahramanmaraş on 13 October 2026 by Ahmed Gadalla, Founder and Chairman of Alushibe Holding Group, and Mehmet Sait Kanbur, Chairman of MADO, the agreement grants Alushibe exclusive rights to develop and operate MADO in Libya, the brand's 36th country. Alushibe will invest US$7 million in the first phase: 7 cafés and 350 jobs, beginning in Benghazi before Tripoli and other major cit
U.S. Bancorp Announces New U.S. Bancorp Global Funds Brand29.10.2026 10:00:00 EET | Press release
U.S. Bancorp today announced its new fund platform, U.S. Bancorp Global Funds, and its first offering, an offshore liquidity fund domiciled in Ireland, the U.S. Bancorp Liquidity – USD Treasury CNAV Fund. U.S. Bancorp Global Funds was created to support U.S. Bancorp’s growing international presence. It establishes a framework for future investment offerings and reflects U.S. Bancorp’s expanding presence in global markets. Investment products offered under the brand are established through U.S. Bancorp Global Funds ICAV, an Ireland-domiciled UCITS umbrella fund structure. The U.S. Bancorp Liquidity – USD Treasury CNAV Fund is the first offering introduced under the new brand. The U.S. Bancorp Liquidity – USD Treasury CNAV Fund is designed for investors outside the United States seeking to preserve capital while accessing a U.S. Treasury-focused liquidity solution within a regulated offshore structure. Domiciled in Ireland as a UCITS fund, it invests primarily in short-term U.S. Treasury
Element Biosciences Launches AVITI Dx™, Bringing CE-Marked IVD Sequencing to Ten EU Countries29.10.2026 10:00:00 EET | Press release
Element Biosciences, Inc. today announced the commercial launch of AVITI Dx, the company's first CE-marked in vitro diagnostic (IVD) sequencing platform under the European Union's In Vitro Diagnostic Regulation (EU IVDR). AVITI Dx integrates Element’s AVITI™ sequencing system, dedicated reagents, and software designed to meet applicable IVDR requirements and support regulated clinical laboratory workflows. The system is launching commercially in ten EU countries: the Netherlands, Germany, France, Italy, Spain, Austria, the Czech Republic, Latvia, Romania, and Poland, with additional markets planned through a phased approach. Developed and manufactured under Element's ISO 13485-certified quality management system, AVITI Dx is a Class A IVD sequencing system supported by IVDR-compliant reagents and software. Built on the same industry-leading ABC™ chemistry that powers Element's other solutions, AVITI Dx delivers the high-quality performance AVITI is known for, with the flexibility and s
Positively Languages Launches, Expands With Malta School and Opens New London Premises29.10.2026 10:00:00 EET | Press release
Positively Languages, a leading language learning business, is unveiling its new brand today. Formerly known as Kaplan Languages Group, (which Inspirit Capital acquired in May 2026), the business is also expanding its portfolio with the opening of a new school in Malta and a new premises in London. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261028449595/en/ Positively Languages, formerly known as Kaplan Languages Group, has taught English, French and German to more than one million students from 140 countries over the past 20 years. The new brand name ‘Positively Languages’ is built around the principle that ‘experience moves you forward’ which forms the backbone of the future growth of the business; new products based on experiences, new schools in the heart of key cultural cities. Positively Languages is also excited to announce the opening of a new school on the Mediterranean island of Malta, known as Positively Langu
IQM Demonstrates Entanglement Across a Complete 54-Qubit Processor, Bringing Full-Chip Performance to Cloud Users29.10.2026 09:00:00 EET | Press release
IQM Quantum Computers (Nasdaq: IQMX), a global leader in superconducting quantum computers, today announced that its cloud-accessible IQM Emerald system has fully entangled all 54 qubits on the chip simultaneously, a result that shows the system’s computational quality holds up when every qubit is put to work at once. IQM’s cloud customers now have access to that same full-chip performance, so their computations can draw on the entire processor rather than a fraction of it. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029191153/en/ IQM measured a fidelity of 0.515 at 40 qubits without readout error mitigation (REM) and 0.516 at the full 54 qubits with REM applied, both above the classical threshold of 0.500 that separates genuine entanglement from noise. These results rank among the strongest reported for any commercially available quantum computer, giving customers access to state-of-the-art, high-quality processors. U
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom